A cartoon usurps Aesop's tortoise and the hare tale to humorously capture the difference between traditional medtech firms and their upstart wearable devices brethren.
News & Features
IBM is entering healthcare by leveraging its Big Data capabilities and cloud platform, and partnering with Apple, J&J and Medtronic. Why is the partnership notable?
In late 2013, media coverage of power morcellators, a tool used during laparoscopic hysterectomies, drew attention to the controversy around the device.
HeartWare's HVAD left ventricular assist device for heart failure showed non-inferiority in stroke-free survival, but a significantly higher rate of strokes in the first cohort of the device's trial for a destination therapy indication.
A cardiologist and electrophysiologist familiar with Boston Scientific's novel products bets one has a very bright future ahead.
A new test aims to improve the subjective visual practice of embryo selection in vitro fertilization with better imaging and data.
Thoratec's HeartMate II left ventricular assist device shows good survival outcomes versus optimal medical management at one year.
CDC provides pending recognition status to digital health companies whose online versions of its National Diabetes Prevention Program is helping at-risk people from getting Type II diabetes.
By overcoming stacked tolerance issues and improving medical device quality, dry PTFE lubricants are a powerful addition to an engineer’s bag of tricks.
After making a $40 million investment in 2013, St. Jude Medical is paying $175 million to bring Spinal Modulation, a neurostimulation company, within its fold.
FDA announces a home-use device labeling pilot program intended to give patients and caregivers who use medical devices at home better access to thorough information and instructions for those devices.
Recent media coverage of adverse events related to morcellators and duodenoscopes exposes the incompetence of FDA's Center for Devices and Radiological Health.
FDA reports that it received over 900 adverse event reports between Essure's approval in 2002 and late 2013.